No. 19-1451

Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc.

Lower Court: Federal Circuit
Docketed: 2020-07-02
Status: Denied
Type: Paid
Experienced Counsel
Tags: administrative-law appointments-clause constitutional-challenge federal-circuit forfeiture ksr-international-co-v-teleflex-inc obviousness patent-act patent-law patent-trial-and-appeal-board pending-case separation-of-powers
Key Terms:
Patent Trademark TradeSecret Privacy JusticiabilityDoctri
Latest Conference: 2020-09-29
Question Presented (AI Summary)

Whether a court can refuse to entertain a constitutional, separation-of-powers challenge based on an intervening change of law on the grounds of forfeiture

Question Presented (from Petition)

QUESTIONS PRESENTED While Sanofi’s appeal was pending before the Federal Circuit, the court decided Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019), holding that Administrative Patent Judges (APJs) on the Patent Trial and Appeals Board (PTAB) were appointed in violation of the Appointments Clause, and vacated and remanded the APJs’ final written decision for redetermination by properly appointed APJs. But the Federal Circuit subsequently held that this change in law applies only to parties who raised an Appointments Clause challenge in their opening appellate brief, and refused to apply its new law to all other parties whose appeals were pending when Arthrex was decided. Thus, in the decision below, the Federal Circuit refused to vacate and remand the PTAB’s decisions—issued by judges—because Sanofi had not raised such a challenge in its opening brief, and affirmed the PTAB’s finding that the challenged patents were invalid as obvious. The questions presented are: 1. Whether, in a pending case, a court can refuse to entertain a constitutional, challenge based on an intervening change of law on the grounds of forfeiture. 2. Whether the Federal Circuit’s obviousness holding is an unwarranted expansion of this Court’s decision in KSR International Co. v. Teleflex, Inc., 550 U.S. 398 (2007), and is inconsistent with the Patent Act.

Docket Entries

2020-10-05
Petition DENIED.
2020-09-09
DISTRIBUTED for Conference of 9/29/2020.
2020-09-08
Reply of petitioner Sanofi-Aventis Deutschland GmbH filed. (Distributed)
2020-08-24
Brief of respondent Mylan Pharmaceuticals Inc. in opposition filed.
2020-07-29
Motion to extend the time to file a response is granted and the time is extended to and including August 24, 2020.
2020-07-28
Motion to extend the time to file a response from August 3, 2020 to August 24, 2020, submitted to The Clerk.
2020-06-26
Petition for a writ of certiorari filed. (Response due August 3, 2020)

Attorneys

Mylan
Douglas H CarstenWilson Sonsini Goodrich & Rosati, Respondent
Douglas H CarstenWilson Sonsini Goodrich & Rosati, Respondent
Mylan Pharmaceuticals Inc.
Steffen Nathanael JohnsonWilson Sonsini Goodrich & Rosati, Respondent
Steffen Nathanael JohnsonWilson Sonsini Goodrich & Rosati, Respondent
Richard Lee Torczon Jr.Wilson Sonsini Goodrich and Rosati PC, Respondent
Richard Lee Torczon Jr.Wilson Sonsini Goodrich and Rosati PC, Respondent
Sanofi-Aventis Deutschland GmbH
Adam Baker BanksWeil, Gotshal & Manges LLP, Petitioner
Adam Baker BanksWeil, Gotshal & Manges LLP, Petitioner